CLS Holdings USA Inc. (OTCMKTS:CLSH) Share price Stays Strong Despite DOJ Comments

Last week a fund of marijuana-based stocks dropped more than 9 percent in value and, as a sign of how mainstream marijuana has become. Most shares dipped only intraday after the DOJ commented that the feds and the states are not finished butting heads over recent widespread legalization.

Last Thursday may well turn out to be a pivotal moment in the marijuana industry’s evolution as a political force. Nearly 70 percent of Americans believe in some form of legalized marijuana, but does the nascent industry have the sway to rewrite nearly 50 years of federal drug policy? Or will it remain a splintered coalition of investors, libertarians, concerned parents of sick kids, cancer sufferers, and traumatized veterans, who have the numbers but not the concentrated lobbying effort necessary to once and for all remove marijuana from the crosshairs of federal drug enforcement?

Stock Analysis

A push by the company to strengthen its cannabis production capabilities appears to have strengthened investors’ confidence on its long-term prospects. The stock is currently trading in an uptrend after gaining more than 50% in response to recent positive news.

For the full year, CLS Holdings USA Inc. (OTCMKTS:CLSH) is up by more than 80%. Given the strength of the upward momentum, the stock should be able to register a new 52-week high as it is currently trading in tight $0.70 to $0.75 range. Lower immediate support looks to be the $0.60 mark. CLS Holdings USA Inc. (OTCMKTS:CLSH) closed the year just off the December high of $0.94 as it continues to affirm plans to double its cannabis growth production capacity.

Recent News

Jan 8…  Here’s the comments from management that was released today regarding the comments from AG Jeff Sessions: http://www.marketwired.com/press-release/cls-holdings-usa-comments-on-recent-department-of-justice-guidance-otcqb-clsh-2244191.htm

Jan 3 … The company announced that it has received a notice of allowance from the U.S. patent office for its proprietary extraction and conversion methodology.

The proprietary extraction process differs from others that typically use ethanol, supercritical CO2 or butane. The resulting finished product is cleaner and provides for more Delta 9 THC. The Company intends to deploy its proprietary extraction and conversion technology upon completion of its pending acquisition of Oasis Cannabis. Additionally, the Company will look to license its patented extraction process.

Jeff Binder, Chairman and CEO of CLS, stated, “Extraction is a very important and valuable process as the quality and value of the finished product is largely impacted by the quality of its extraction. We are focused on increasing yields and the quality of yields and feel our process gives us a major leg up relative to others in the industry. We have dedicated considerable amounts of resources to this endeavor and to receive this allowance from the US patent office is a milestone for the company. I am truly appreciative of all the efforts and contributions of our team and wish to personally thank our chief scientist and co-founder, Ray Keller.”

Acquisition
Dec. 11… Oasis is an exciting acquisition target as it is set to expand CLS Holdings USA Inc. (OTCMKTS:CLSH) footprint in the business of growing, extracting and processing cannabis products for retail. The company comes into the deal with a growing, conversion and extraction facility that produced $150,000 in gross revenue last month.

The acquisition should be of great benefit to CLS Holdings on the fact that Oasis already generates revenues and has permits to operate dispensaries and deliver products to end consumers.
The parent company also stands to use its proprietary extraction methods to increase the yields from Oasis grow and cultivation businesses. CLSH may also scale Oasis retail business by opening franchises throughout Nevada as well as in other states that have approved marijuana sale.

In addition, the company’s cash balance destined to receive a significant boost upon the closing of the definitive acquisition agreement given that Oasis dispensary serves over 300 customers on a daily basis.
“Since we began this process to acquire Oasis Cannabis a couple of months ago, we have witnessed firsthand its growth and traction in visitors and revenue. We are very pleased with the trends at its grow and retail dispensary and are enthusiastic to move forward to an anticipated closing in the first quarter of 2018,” said CEO, Jeff Binder.

Management Appointment

The appointment of, David Lamadrid, as the President and Chief Financial Officer appears to have strengthened investor confidence in CLS Holdings USA Inc. (OTCMKTS:CLSH). He joins the company with vast experience in management and finance required to lead the firm through the next phase of growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSH and receive breaking news on other hot stocks by signing up for our free newsletter!

FacebookTwitterGoogle+PinterestLinkedIn
acquisitionbiotechcannabiscls holdingsmerger
PREVIOUS ARTICLE
CELLECTAR (NASDAQ: CLRB) JUMPS 35% ON EXPANSION OF PHASE 2 TRIAL

Monica Gray
Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Leave a Reply
YOUR EMAIL ADDRESS WILL NOT BE PUBLISHED. REQUIRED FIELDS ARE MARKED *

Comment

Name *

Email *

Website

POST COMMENT

AURORA CANNABIS IN (OTCMKTS:ACBFF)

CLS Holdings USA (OTCMKTS:CLSH) Receives a Notice of Allowance from the U.S. Patent Office.

Shares of CLS Holdings USA Inc. (OTCMKTS:CLSH) are trading higher in the wake of the company announcing that it has received a notice of allowance from the U.S. patent office for its proprietary extraction and conversion methodology.

The proprietary extraction process differs from others that typically use ethanol, supercritical CO2 or butane. The resulting finished product is cleaner and provides for more Delta 9 THC. The Company intends to deploy its proprietary extraction and conversion technology upon completion of its pending acquisition of Oasis Cannabis. Additionally, the Company will look to license its patented extraction process.

Jeff Binder, Chairman and CEO of CLS, stated, “Extraction is a very important and valuable process as the quality and value of the finished product is largely impacted by the quality of its extraction. We are focused on increasing yields and the quality of yields and feel our process gives us a major leg up relative to others in the industry. We have dedicated considerable amounts of resources to this endeavor and to receive this allowance from the US patent office is a milestone for the company. I am truly appreciative of all the efforts and contributions of our team and wish to personally thank our chief scientist and co-founder, Ray Keller.”

Stock Analysis

A push by the company to strengthen its cannabis production capabilities appears to have strengthened investors’ confidence on its long-term prospects. The stock is currently trading in an uptrend after gaining more than 50% in response to recent positive news.

For the full year, CLS Holdings USA Inc. (OTCMKTS:CLSH) is up by more than 80%. Given the strength of the upward momentum, the stock should be able to register a new 52-week high as it is currently trading in tight $0.64 to $0.69 range. Lower immediate support looks to be the $0.45 mark. CLS Holdings USA Inc. (OTCMKTS:CLSH) should close the year on the high as it continues to affirm plans to double its cannabis growth production capacity.

Recent Oasis Cannabis Acquisition News

Oasis is an exciting acquisition target as it is set to expand CLS Holdings USA Inc. (OTCMKTS:CLSH) footprint in the business of growing, extracting and processing cannabis products for retail. The company comes into the deal with a growing, conversion and extraction facility that produced $150,000 in gross revenue last month.

The acquisition should be of great benefit to CLS Holdings on the fact that Oasis already generates revenues and has permits to operate dispensaries and deliver products to end consumers.
The parent company also stands to use its proprietary extraction methods to increase the yields from Oasis grow and cultivation businesses. CLSH may also scale Oasis retail business by opening franchises throughout Nevada as well as in other states that have approved marijuana sale.

In addition, the company’s cash balance destined to receive a significant boost upon the closing of the definitive acquisition agreement given that Oasis dispensary serves over 300 customers on a daily basis.
“Since we began this process to acquire Oasis Cannabis a couple of months ago, we have witnessed firsthand its growth and traction in visitors and revenue. We are very pleased with the trends at its grow and retail dispensary and are enthusiastic to move forward to an anticipated closing in the first quarter of 2018,” said CEO, Jeff Binder.

Management Appointment

The appointment of, David Lamadrid, as the President and Chief Financial Officer appears to have strengthened investor confidence in CLS Holdings USA Inc. (OTCMKTS:CLSH). He joins the company with vast experience in management and finance required to lead the firm through the next phase of growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSH and receive breaking news on other hot stocks by signing up for our free newsletter!

Diana Containerships Inc (NASDAQ:DCIX)

Stock Rises Despite Q3 Losses by Diana Containerships Inc (NASDAQ:DCIX)

Diana Containerships Inc (NASDAQ:DCIX)

Diana Containerships Inc (NASDAQ:DCIX) shares are up 81%, to $12, in pre-market trading after the shipping company reported a Q3 2017 loss of $8.7 million. On a per-share basis, the loss amounted to $128.67. DCIX shares, a favorite of day-traders, hit a low of $6.35 at 7:13 AM EST and a high of $9.50 at 7:56. Volume has been light to moderate.

Diana Containerships Inc (NASDAQ:DCIX)

The shipping company posted revenue of $6.7 million in the period. Greece-based Diana Containerships Inc (NASDAQ:DCIX) is a global shipping provider. The company’s containerships are employed primarily on time charters with leading liner companies carrying containerized cargo along worldwide shipping routes.

Diana Q3 Financials

Net income for the nine months ended September 30, 2017 amounted to $20.4 million, compared to a net loss of (-$140.6) million for the same period of 2016. The net income for the nine months ended September 30, 2017 reflected a gain from a debt write-off, arising from the settlement agreement with respect to the secured loan facility with the Royal Bank of Scotland plc. The specific gain, net of related expenses, amounted to $42.2 million.

The loss for the nine months ended September 30, 2016 reflected the result of impairment charges for seven of the company’s vessels. Time charter revenues, net of prepaid charter revenue amortization, for the nine months ended September 30, 2017, amounted to $16 million, compared to $27.7 million for the same period in 2016.

Diana Lawsuit

A number of law firms are pursuing class action lawsuits against Diana Containerships Inc (NASDAQ:DCIX). The complaints generally allege that the company made materially false and misleading statements regarding the company’s business, operational, and compliance policies.

Specifically, the company made false and/or misleading statements and/or failed to disclose that: (i) through his control of Diana, Symeon Palios caused Diana to sell its common shares and securities convertible into common shares to an entity named Kalani Investments Limited (“Kalani”) at a significant discount to market price and to file registration statements so that Kalani could resell these shares into the market; (ii) when Kalani’s sales of DCIX stock caused the price of Diana stock to drop, the company would reverse split the stock, causing a specific number of outstanding shares to be merged into a single share, thereby raising the price of Diana stock; (iii) then Diana would again sell securities to Kalani and the same pattern of transactions would ensue.

By October 3, 2017, as a result of defendants’ ongoing dilutive and manipulative conduct, the price of Diana common stock had declined to close at $0.47 per share on an unadjusted basis. At this share price, Diana had a market capitalization of less than one million dollars, despite having raised millions of dollars since January 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DCIX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Q3 Earnings Disappoint

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) fell 4.4% as investors reacted to the company’s third quarter financial results and corporate update. The clinical stage pharmaceutical company did not report any revenue for the three months ended September 30, 2017, as it is in the research and development phase.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa’s Pipeline Development

Operating expenses for the quarter totaled $2.1 million and $5.6 million for the first nine months of the year. Research and development expenses in the quarter increased to $0.7 million from $0.1 million reported last year.

During the quarter, Atossa Genetics Inc. (NASDAQ:ATOS) announced preliminary results from a Phase 1 study of its lead candidate drug Endoxifen. The drug met its primary endpoint with no significant safety signal or adverse events.

Atossa Genetics is currently preparing for a Phase 2 study that will evaluate Endoxifen for the treatment of women with mammographic breast density. The study will be conducted in partnership with the Stockholm South General Hospital in Sweden.

“We are very pleased with our recent clinical progress with our Endoxifen programs. Preliminary results from our Phase 1 study show that all objectives of both our proprietary topical and oral formulations of Endoxifen have been met. We recently raised capital to support advancement of our Endoxifen,” said CEO, Steve Quay

Atossa Genetics Inc. (NASDAQ:ATOS) underperformance continued in the market following the third quarter financial results. The stock is currently languishing as it closes in on its 52-week low of $0.32 a share. The stock has shed more than 70% in market value since the start of the year. As it stands, the stock needs a new catalyst if it is to bounce back.

ATOS Public Offering Impact

Declining investor confidence in Atossa Genetics follows the pricing of a public offering of the company’s common shares at a deep discount. The move did not go well with investors. The public offering’s pricing triggered a selloff of the stock to current lows.

Atossa Genetics issued 11.5 million shares of common stock priced at $0.44 a share. The company also offered underwriters the option of purchasing an additional 1 million shares pursuant to the over-allotment option.

Gross proceeds before deduction of underwriting discounts commissions and the offering costs were approximately $5.5 million. Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

RadiSys Corporation (NASDAQ:RSYS)

RadiSys Corporation (NASDAQ:RSYS) Implodes As Loss Spooks Investors

RadiSys Corporation (NASDAQ:RSYS)

Shares of RadiSys Corporation (NASDAQ:RSYS) fell to a new 52-week low after the global leader in Open telecom solutions reported disappointing third quarter financial results. The stock fell 32.03% in Wednesday’s trading session to end the day at $0.87 a share.

RadiSys Corporation (NASDAQ:RSYS)

Radisys Q3 Financial Results

Investors pushed the stock lower on the company reporting a net loss of (-$15.4) million or (-$0.39) a share, more than double a net loss of (-$7.6) million reported last year. Gross margin in the quarter shrunk to 10.8% compared to 29.4% in the third quarter of 2016.

Concerned with the spiraling net loss, RadiSys Corporation (NASDAQ:RSYS) has implemented a revised go-to-market strategy that will allow it to refine its cost structure. Plans are also underway to advance the current funnel of prospective and existing customer opportunities.

RadiSys Corporation (NASDAQ:RSYS) has generated revenues of $11.3 million up from $10.4 million reported last year. However, it was a decline from $11.4 million reported in the second quarter. The company attributes the decline to timing of professional services programs whose impact will be felt in the fourth quarter

“Importantly, we made tangible progress in the third quarter towards converting proof-of-concepts into commercial wins as evidenced by the two new Media Engine VoLTE wins as well as our first commercial award for deployment of our new Flow Engine appliance, the TDE-200,” said Brian Bronson, Radisys President, and Chief Executive Officer.

For the fourth quarter, the company expects revenues of between $29 million and $33 million, helped by certain MediaEngine orders. Radisys also expects a net loss of between (-$0.19) and (-$0.13) a share.

RadiSys-Mavenir Partnership

Separately, RadiSys Corporation (NASDAQ:RSYS) and Mavenir have joined forces to enable Communications services providers commercially deploy Mobile Central Office Re-architected as a Datacenter (M-CORD). The open reference solution is designed to provide capabilities for unlocking innovation across open networking ecosystem with cloud economies.

Under the partnership, RadiSys Corporation (NASDAQ:RSYS) is to integrate Maveni’r’s carried grade vEPC into its M-CORD Distribution. The integration should accelerate CSPs path to network integration.

“We’re pleased to partner with Mavenir to advance CSPs’ ability to break vendor lock-in, accelerate service innovation and lower CapEx and OpEx through commercial deployment of the M-CORD architecture,” said Neeraj Patel, vice president and general manager, MobilityEngine, Radisys.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RSYS and receive breaking news on other hot stocks by signing up for our free newsletter!

Envoy Group Corp $ENVV

Investors Run from Envoy Group Corp (OTCMKTS:ENVV)

Envoy Group Corp (OTCMKTS:ENVV)

Shares of Envoy Group Corp (OTCMKTS:ENVV) are down over 60% after the OTC markets designated trading in the shares as “Caveat Emptor” – buyer beware. Volume for ENVV shares is larger than normal Over 4 million shares traded hands by lunch in a stock that has an average daily volume of barely more than 600,000.

The “Caveat Emptor” designation is typically assigned to a stock when there may be reason to exercise additional care and perform thorough due diligence before making an investment decision in that security. A review of Envoy Group Corp (OTCMKTS:ENVV) publicly available information reveals that care may indeed be warranted.

According to the OTC Markets website, Envoy Group Corp (OTCMKTS:ENVV) has over 92 million shares outstanding with a market cap of over $77 million. The float on the stock (the number of shares actually available for trading) was 23.7 million shares. The company last filed a form 10-Q with the U.S. Securities and Exchange Commission on July 11, 2017 for the period ending July 31, 2016. Interestingly, the company self-reported its industry sector as “Nursing and Personal Care Facilities”. Even more interesting is that a quick glance at the balance sheet reveals the company reporting assets, and revenues, of $0.00 – zero.

The website that visitors are directed to from the OTC Markets Company Profile page is that of BitReturn. BitReturn is presented to the public as a subsidiary of Envoy Group Corp (OTCMKTS:ENVV) dealing in bitcoin. No mention of nursing or healthcare is found on any website attributed to Envoy Group Corp.

It appears that Envoy Group Corp (OTCMKTS:ENVV) may have been capitalizing on the bitcoin frenzy as investors tried to search out low-cost stocks in an effort to leverage the growth of the burgeoning industry.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENVV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Anavex life sciences

Bad Week for Anavex Life Sciences Corp (OTCMKTS:AVXL)

Anavex Life Sciences Corp (OTCMKTS:AVXL)

Shares of Anavex Life Sciences Corp (OTCMKTS:AVXL) dropped over 26% for the week. The weekly performance would have been worse, however a heavy buying spree at the end of Friday’s session pushed the shares up from their $3.64 daily low to close out the week at $4.21. YTD AVXL shares are up over 6% but are down over 40% for the year.

Anavex Life Sciences Corp (OTCMKTS:AVXL), headquartered in New York City, NY, is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system diseases, pain, and various types of cancer. Anavex’s lead compound ANAVEX™ 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases such as Rett syndrome. ANAVEX™ 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  Results from preclinical studies showed promise to halt and/or reverse the course of Alzheimer’s disease. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX™ 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX™ 2-73 into a Parkinson’s disease clinical trial.

On July 20, 2017, Anavex Life Sciences Corp (OTCMKTS:AVXL) announced the appointment of Andrew J. Cole, M.D., F.R.C.P.(C.) to its Scientific Advisory Board. Dr. Cole is Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical School. He trained in Neurology and Clinical Neurophysiology at the Montreal Neurological Institute, and then moved to Johns Hopkins University School of Medicine where he was Assistant Professor of Neurology. Dr. Cole then came to Massachusetts General Hospital in 1992 where he started and developed the MGH Epilepsy Service and founded the MGH Pediatric Epilepsy Service. In addition to research and clinical work, Dr. Cole lectures frequently throughout the United States and internationally, and has been a visiting professor at numerous institutions in the U.S.A. and abroad.

AVXL shareholders would welcome positive news. Each year they have experienced per share losses. In 2012 the per share loss was (-$1.18) but the loss did shrink to (-$0.42) by 2016. Still, for a biotech with no revenues, AVXL shareholder’s patience may be wearing thin.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVXL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Mobileiron Inc (NASDAQ:MOBL)

The Momentum of Mobileiron Inc (NASDAQ:MOBL)

Mobileiron Inc (NASDAQ:MOBL)

Last October, Mobileiron Inc (NASDAQ:MOBL) established its 52-week low of $2.56; and last week MOBL shares established their 52-week high of $6.78. MOBL shares have had an excellent run as of late. YTD shares are up over 66%, and for the year shares have nearly doubled. The share volume on Friday was over 2.8 million while the 30-day average volume is under 800,000.

Mountain View, CA-based MobileIron, Inc. (NASDAQ:MOBL) provides mobile IT platforms that enable enterprises to secure and manage mobile applications, content, and devices. The MobileIron platform offers an enterprise mobility management (EMM) solution that configures and delivers applications to smartphones, tablets, laptops, and desktops running operating systems. Global sectors that Mobileiron serves comprises the financial services, government, healthcare, legal, manufacturing, retail, technology, and telecommunications industries.

Sales growth has been stellar for MobileIron, Inc. (NASDAQ:MOBL). In 2012 the company posted a sales figure of $40.9 million. That figure increased annually and by 2016 sales were a reported $163.9 million. On the downside, earnings have been disappointing for shareholders. In 2012 the per share loss was (-$0.62) and that was followed by losses of (-$0.44), (-$1.30), (-$1.07), and for 2016, (-$0.78).

Investment analysts are not in unison on MOBL share’s prospects. Two rate the shares as a “Strong Buy”, while one each rate the shares either a “Buy”, “Hold”, or “Sell”. Their consensus price target is $5.50 – $0.75 below Friday’s close.

Last week the company announced that it will release its second quarter fiscal year 2017 earnings on Thursday, July 27, 2017. Interested parties may access the call by dialing 1-855-327-6837 in the U.S. or 1-631-891-4304 from international locations. There is little doubt that analysts will be playing close attention.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MOBL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Cerulean Pharma Inc (NASDAQ:CERU)

Cerulean Pharma Inc (NASDAQ:CERU) And Dare Biosciences Complete Merger

Cerulean Pharma Inc (NASDAQ:CERU)

Dare Biosciences has become a wholly owned subsidiary of Cerulean Pharma Inc. (NASDAQ:CERU) after the closing of a stock purchase agreement agreed between the two companies in March. Investors reacted to the news sending the stock up by 3.98% to close the day at $0.66 a share.

Combined Company Mission

The combined company is to focus on the development and commercialization of innovative products for women’s reproductive health. Cerulean Pharma Inc (NASDAQ:CERU)’s goal is to fill the gap in the niche market by taking products from innovation through development.

Dare Biosciences is backed by a team of experienced management executives with global experience in women’s healthcare. Ovaprene becomes the combined company’s lead candidate drug designed to address the $19 billion global contraception market. The non-hormonal intravaginal ring is designed to provide protection over multiple weeks.

“We are thrilled to have the opportunity to grow our business as a public company. Women’s reproductive health encompasses a broad spectrum of categories, many of which have unmet needs. Daré is committed to developing a portfolio that expands options, improves outcomes, and enhances safety for women,” said Sabrina Martucci Johnson Dare Biosciences CEO.

Stock Purchase Agreement

Dare Biosciences and Cerulean Pharma Inc. (NASDAQ:CERU) entered into a stock purchase agreement as part of a merger agreement in March. Cerulean agreed to divest some of its assets as part of an effort that sought to raise money to help fund the combined company’s operations. The company raised $1.5 million from the sale of its clinical product candidates CRLX 101 and CRLX301 to Blue Link Pharmaceuticals.

Under the terms of the agreement, holders of Dare equity now hold 51% of the parent company capital stock. Cerulean Pharma Inc (NASDAQ:CERU) is also to change its name to Dare Biosciences effective July 20, 2017. The company will continue to trade on the NASDAQ but under the new name and stock symbol “DARE”.

A 1:10 reverse stock-split of the combined company’s stock is also to be effected. The reverse stock-split will result in the consolidation of every ten shares of Cerulean Pharma Inc. (NASDAQ:CERU)’s stock issued for one issued and outstanding shares. No fractional shares are to be issued. The total number of shares issued and outstanding after the split will be approximately 6,047,200.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERU and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Sinovac Biotech Ltd. (NASDAQ:SVA)

Sinovac Biotech Ltd. (NASDAQ:SVA) Enters into Definitive Agreement

Sinovac Biotech Ltd. (NASDAQ:SVA)

Sinovac Biotech Ltd. (NASDAQ:SVA) has announced entering into an amalgamation agreement with its parent company Sinovac (Cayman) Limited and Sinovac Amalgamation Sub Limited, a fully owned subsidiary of Sinovac (Cayman) Limited. Under the agreement, Sinovac will be acquired by the parent company in a deal that is expected to cost $401.8 million. Sinovac Biotech Ltd is one of the major providers of biopharmaceutical products in China.

Under the terms of the amalgamation agreement, Sinovac (Cayman) Limited will take over the ownership of Sinovac Biotech Ltd for a cash deal amounting to US$7.00 per common share of the Company. This translates to a premium of 32.1% and 30%, respectively when compared to the 30- and 60-trading day volume-weighted average price of the stock before the company made the announcement on February 1, 2016.

The consideration represents an increase of around 13.3% from the initial US$6.18 per Share price offer in the deal that was announced earlier on February 1, 2016.

After sealing the amalgamation deals, the parent company will be owned by a group of companies comprised of C-Bridge Healthcare Fund II, L.P, Mr. Yin, SAIF, Advantech Capital L.P, Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.As of June 23, 2017, this Consortium had already owned around 29.5% of the company’s total issued and outstanding shares.

According to the terms of the amalgamation agreement, after the acquisition, the Amalgamation Sub will be combined into one company. After the agreement, all issued and outstanding shares of the amalgamation will be canceled and their holders will be given $7.00 per share in cash.

The buying Consortium plans to fund the deal using a cash pool collected from Vivo Capital, Advantech Capital, and C-Bridge Capital or their respective partners and affiliates. The transaction has been approved the boards of directors of all company’s involved.

The amalgamation is expected to be completed in the second quarter of the 2017 financial year and its completion is subject to customary closing conditions. It will also have to be approved by at least two-thirds of the shareholders of all companies involved.

Sinovac Biotech Ltd. (NASDAQ:SVA) gained 12.46% and closed the day at $6.41.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SVA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.